Table 1.
Most frequent (all grade) adverse events of tyrosine kinase inhibitors used in thyroid cancer.
| Adverse event | Sunitinib [37, 39] |
Sorafenib [41–45] |
Vandetanib [47–49] |
Motesanib [50] |
Axitinib [53] |
Pazopanib [55] |
Lenvatinib [58] |
|---|---|---|---|---|---|---|---|
| Hypertension |
22% | 48% | 33% | 27% | 28% | — | 64% |
| Diarrhea |
37% | 77% | 57% | 41% | 48% | 73% | 45% |
| Fatigue |
45% | 48% | 43% | 41% | 50% | 78% | 55% |
| Weight loss |
— | 54% | 30% | 22% | 25% | 64% | 43% |
| Nausea |
— | 22% | 37% | 26% | 33% | 73% | 44% |
| Hand-foot skin reaction |
35% | 91% | — | — | 15% | — | — |
| Rash | — | 73% | 46% | — | 15% | 75% | — |